NeuroScientific

ASX:NSB

ASX Announcement
06 November 2025

Neuroscientific Appoints Clinical & Scientific Advisory Board

Advisory Board will provide guidance on future innovation and clinical indications

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) ("NSB" or the **"Company"),** an innovative Australian biotechnology company developing novel technologies targeted at immune-mediated inflammatory diseases, is pleased to announce the appointment of the Clinical & Scientific Advisory Board ("**Advisory Board**") with immediate effect.

The Advisory Board has been created to provide ongoing guidance with respect to scientific innovation, product development, clinical indications, and patient treatment. The Advisory Board will be led by NSB's Chief Medical Officer, Dr Catherine Cole, and will include Dr Marian Sturm, NSB's Chief Scientific Officer, along with the following members:

- **Dr Ashley Irish, MBBS FRACP:** Dr Irish is a Clinical Professor at the University of Western Australia and a Clinical Nephrologist and Renal Transplant Lead Clinician at Fiona Stanley Hospital, with expertise in clinical research in dialysis and renal transplantation, chronic kidney disease, cardiovascular disease, renal paraprotein disorders, dyslipidaemias and thrombosis in renal disease and glomerulonephritis. Dr Irish provides inpatient and outpatient services at Fiona Stanley Hospital, St John of God Subiaco Hospital and St John of God Murdoch Hospitals, and visits the Pilbara on a regular basis. He is the Clinical Lead for West Australian Country Health Service (WACHS) Renal Program.
- **Dr Lena Thin, MClinRes MBBS:** Dr Thin is a Consultant Gastroenterologist at Fiona Stanley Hospital with a special interest in Inflammatory Bowel Disease. Dr Thin is the Principal Investigator for the IBD Research unit at Fiona Stanley Hospital, recruits to multiple international clinical trials and sits on numerous advisory boards. She is an executive member for the Australian New Zealand IBD research consortium and was recently an IBD faculty member for the Gastroenterology Society of Australia. Dr Thin has a keen interest in managing complex IBD patients and improving quality of care for IBD patients. Dr Thin is an Adjunct Senior Clinical Lecturer with the University of Western Australia's medical school. She has extensive experience with performing intestinal ultrasounds, is a certified intestinal sonographer with IBUS and GENIUS and an accredited trainer with GENIUS.
- **Dr Michael Musk, MBBS FRACP:** Dr Musk is a Respiratory Physician and Medical Director at Fiona Stanley Hospital. He serves as Head of Service, Advanced Lung Disease Unit at Fiona Stanley Hospital and specialises in all aspects of general respiratory medicine with special interests in Lung Transplantation, Interstitial Lung Disease, Pulmonary Vascular

Disease, Surgical management of Emphysema. Michael has been the Principle Investigator of numerous clinical trials in treatment of Idiopathic Pulmonary Fibrosis, lung transplantation, Bronchiolitis, and Bronchiectasis with a special research interest in understanding the pathogenesis of post lung transplant obliterative bronchiolitis. Dr Musk is a member of the Transplant Society of Australia and New Zealand, previous Chair of Lung Transplant Advisory Committee of the Thoracic Society of Australia and New Zealand and member of International Society of Heart and Lung Transplantation.

- **Professor Yuben Moodley, MBBS FRACP MD PhD:** Prof Moodley is a Consultant Respiratory Physician at Fiona Stanley Hospital, Professor of Respiratory Medicine at the University of Western Australia, and the Co-Deputy Director and Research Leader of the Cell Biology Group at the Institute for Respiratory Health. He is also a chief investigator in the Centre for Research Excellence in Pulmonary Fibrosis and serves on the scientific advisory board of Roche and Boehringer Ingelheim, as well as the steering committee for the Interstitial Lung Disease registry in Australia. Prof Moodley's areas of expertise include pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) and cell biology of the lung. His research interests include finding biomarkers the diagnosis and monitoring of lung conditions such as Idiopathic Pulmonary Fibrosis (IPF) and finding novel therapies for COPD and pulmonary fibrosis, with further focus on the epigenetic and molecular pathogenesis of IPF.

Dr Catherine Cole commented "*I am delighted to be working closely with the distinguished members on our Advisory Board to further develop NSB's clinical and scientific strategy for StemSmart™. The combined knowledge and expertise they bring to the table, along with their care for patients with unmet medical needs, will provide a roadmap for future innovation and development at NSB.*"

CEO Nathan Smith said "*With the appointment of our Advisory Board, we now have a strong panel of Key Opinion Leaders across clinical and scientific fields that can support our goal of treating patients with unmet medical needs in immune-mediated inflammatory disorders.*"

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

For more information, please contact:

Nathan Smith
Chief Executive Officer
NeuroScientific Biopharmaceuticals Ltd
ir@neuroscientific.com

Jane Morgan
Investor & Media Relations
Jane Morgan Management
jm@janemorganmanagement.com.au

NeuroScientific

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-inclass or best-in-class biologics addressing significant unmet clinical need.

Targeting Crohn's Disease with StemSmartTM Technology

Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology through a SAS program targeting fistulising Crohn's disease—a severe and treatment-resistant form of the condition. Favourable outcomes will support the Company's progression to a Phase 2 clinical trial to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn's disease. This initiative aligns with NSB's broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn's disease, for whom current therapies remain inadequate.

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.

+61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000